Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Conditions

Breast Adenocarcinoma · Breast Cancer Stage IV · Breast Cancer, Metastatic · Breast Carcinoma · Breast Diseases · Breast Neoplasms · Breast Neoplasms, Male · Breast Cancer · Breast Cancer With Metastatic Bone Disease · Breast Cancers · Breast Neoplasm · Breast Tumors · HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer · HR+ Advanced or Metastatic Breast Cancer · HR+/HER2- Breast Cancer · HRpos Breast Neoplasms · HR-positive, HER2-negative Advanced Breast Cancer · HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer · HR-positive Breast Cancer · Hormone Receptor-Positive Breast Cancer · Hormone Receptor Positive Breast Adenocarcinoma · Hormone Receptor Positive Breast Carcinoma · Hormone Receptor Positive Breast Neoplasms · Hormone Receptor Positive HER-2 Negative Breast Cancer · Hormone Receptor Positive Malignant Neoplasm of Breast · Hormone Receptor Positive Metastatic Breast Cancer · Hormone Receptor Positive, HER2 Negative Breast Cancer · Hormone Receptor Negative Breast Cancer · Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer · Hormone Receptor Positive Breast Cancer · Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer · Hormone Receptor Positive, HER2-negative Neoplasms · Hormone Receptor Positive, HER2-low Neoplasms · Hormone Receptor Positive (HR+), HER2-negative Breast Cancer · Hormone Receptor (HR)-Positive Breast Cancer · Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer · Palbociclib · Ribociclib · Abemaciclib · CDK4/6 Inhibitor · CDK4/6 Inhibitors